Esperion Therapeutics, Inc. (NASDAQ: ESPR) related to its sale to funds managed by ARCHIMED. Under the terms of the proposed transaction, Esperion shareholders are expected to receive $3.16 per share in cash and the right to participate in contingent milestone payments.